Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
SARS-COV2
allogeneic
autologous
immune response
transplant
vaccine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
07
2021
accepted:
17
08
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
The efficacy of Covid-19 vaccine in hematopoietic stem cell transplantation (HSCT) recipients is still unknown. We planned a prospective study to evaluate the immune response after the administration of Covid-19 vaccine in HSCT recipients. Fifty patients previously submitted to HSCT (38 autologous and 12 allogeneic) received the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Serum samples of all patients were tested for SARS-CoV-2 IgG against the Spike glycoprotein, 30 days after the second dose of vaccine. Antibody response was compared to a control group of 45 healthy subjects. Of the 50 patients tested, 12 did not develop any antibody response, including 6 patients undergoing autologous (16%) and 6 allogeneic HSCT (50
Identifiants
pubmed: 34552880
doi: 10.3389/fonc.2021.737300
pmc: PMC8451475
doi:
Types de publication
Journal Article
Langues
eng
Pagination
737300Informations de copyright
Copyright © 2021 Chiarucci, Paolasini, Isidori, Guiducci, Loscocco, Capalbo and Visani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cleve Clin J Med. 1994 Jul-Aug;61(4):308-13
pubmed: 7923750
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
Semin Hematol. 2010 Apr;47(2):115-23
pubmed: 20350658
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246